Search for content, post, videos

Gesynta Pharma prepares Phase II study of GS-248 in endometriosis

Patric Stenberg
Gesynta Pharma has announced the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis. This strategically important decision follows a recent preclinical proof-of-concept study with GS-248 in an advanced model of endometriosis, where disease-modifying p
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.